Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £639 | £646 | £2,600 | £284 |
| Gross Profit | -£639 | -£646 | -£2,600 | -£284 |
| % Margin | – | – | – | – |
| R&D Expenses | £237 | £91 | £0 | £0 |
| G&A Expenses | £4,738 | £4,913 | £942 | £1,397 |
| SG&A Expenses | £5,087 | £4,913 | £942 | £1,397 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£237 | -£91 | £1,988 | £1,306 |
| Operating Expenses | £5,087 | £4,913 | £2,931 | £2,703 |
| Operating Income | -£5,727 | -£5,559 | £3,998 | -£2,703 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | £101 | -£1,138 | £1,544 | -£2,406 |
| Pre-Tax Income | -£5,625 | -£6,696 | -£3,987 | -£5,108 |
| Tax Expense | £0 | £0 | £361 | £2,414 |
| Net Income | -£5,619 | -£6,691 | -£3,979 | -£5,099 |
| % Margin | – | – | – | – |
| EPS | -1.7 | -2.37 | -1.62 | -2.64 |
| % Growth | 28.3% | -46.3% | 38.6% | – |
| EPS Diluted | -1.7 | -2.37 | -1.62 | -2.64 |
| Weighted Avg Shares Out | 3,301 | 2,823 | 2,449 | 1,935 |
| Weighted Avg Shares Out Dil | 3,301 | 2,823 | 2,449 | 1,935 |
| Supplemental Information | – | – | – | – |
| Interest Income | £23 | £85 | £11 | £18 |
| Interest Expense | £272 | £316 | £0 | £2,595 |
| Depreciation & Amortization | £639 | £646 | £564 | £126 |
| EBITDA | -£4,715 | -£5,735 | -£3,423 | -£2,387 |
| % Margin | – | – | – | – |